AR032449A1 - Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina - Google Patents

Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina

Info

Publication number
AR032449A1
AR032449A1 ARP010101263A ARP010101263A AR032449A1 AR 032449 A1 AR032449 A1 AR 032449A1 AR P010101263 A ARP010101263 A AR P010101263A AR P010101263 A ARP010101263 A AR P010101263A AR 032449 A1 AR032449 A1 AR 032449A1
Authority
AR
Argentina
Prior art keywords
cabergoline
cabergolina
solvato
procedure
produce
Prior art date
Application number
ARP010101263A
Other languages
English (en)
Spanish (es)
Inventor
Stefania Megenes
Mario Ungari
Giuliano Ramella
Gianfranco Pallanza
Attilio Tomasi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AR032449A1 publication Critical patent/AR032449A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP010101263A 2000-03-24 2001-03-19 Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina AR032449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline

Publications (1)

Publication Number Publication Date
AR032449A1 true AR032449A1 (es) 2003-11-12

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101263A AR032449A1 (es) 2000-03-24 2001-03-19 Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina

Country Status (31)

Country Link
US (2) US6727363B2 (cg-RX-API-DMAC10.html)
EP (1) EP1272489B1 (cg-RX-API-DMAC10.html)
JP (1) JP4184666B2 (cg-RX-API-DMAC10.html)
KR (1) KR100827558B1 (cg-RX-API-DMAC10.html)
CN (1) CN1188412C (cg-RX-API-DMAC10.html)
AR (1) AR032449A1 (cg-RX-API-DMAC10.html)
AT (1) ATE250601T1 (cg-RX-API-DMAC10.html)
AU (2) AU780747B2 (cg-RX-API-DMAC10.html)
BR (1) BR0109507A (cg-RX-API-DMAC10.html)
CA (1) CA2402836A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20023176A3 (cg-RX-API-DMAC10.html)
DE (1) DE60100858T2 (cg-RX-API-DMAC10.html)
DK (1) DK1272489T3 (cg-RX-API-DMAC10.html)
EA (1) EA005928B1 (cg-RX-API-DMAC10.html)
EE (1) EE05088B1 (cg-RX-API-DMAC10.html)
ES (1) ES2208602T3 (cg-RX-API-DMAC10.html)
GB (1) GB0007308D0 (cg-RX-API-DMAC10.html)
HK (1) HK1052348B (cg-RX-API-DMAC10.html)
HU (1) HUP0300591A3 (cg-RX-API-DMAC10.html)
IL (2) IL150985A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA02009283A (cg-RX-API-DMAC10.html)
MY (1) MY134189A (cg-RX-API-DMAC10.html)
NO (1) NO20024321L (cg-RX-API-DMAC10.html)
NZ (1) NZ521316A (cg-RX-API-DMAC10.html)
PE (1) PE20011140A1 (cg-RX-API-DMAC10.html)
PL (1) PL358253A1 (cg-RX-API-DMAC10.html)
PT (1) PT1272489E (cg-RX-API-DMAC10.html)
SI (1) SI1272489T1 (cg-RX-API-DMAC10.html)
SK (1) SK13582002A3 (cg-RX-API-DMAC10.html)
WO (1) WO2001070740A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200206045B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
RS81804A (sr) * 2002-03-15 2006-10-27 Pharmacia Corporation Postupak za dobijanje kristalnog oblika kabergolina
WO2003078392A2 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
AU2004238833A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
JPH08502759A (ja) 1993-08-18 1996-03-26 アルコン ラボラトリーズ,インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
PL343593A1 (en) 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline

Also Published As

Publication number Publication date
US20040092744A1 (en) 2004-05-13
AU2005203071A1 (en) 2005-08-11
DK1272489T3 (da) 2003-12-15
NZ521316A (en) 2004-05-28
MXPA02009283A (es) 2003-03-12
SK13582002A3 (sk) 2003-04-01
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
AU6211001A (en) 2001-10-03
EA200201016A1 (ru) 2003-02-27
EA005928B1 (ru) 2005-08-25
MY134189A (en) 2007-11-30
HK1052348B (zh) 2005-09-16
ZA200206045B (en) 2003-07-29
GB0007308D0 (en) 2000-05-17
IL150985A0 (en) 2003-02-12
PT1272489E (pt) 2004-02-27
JP4184666B2 (ja) 2008-11-19
KR100827558B1 (ko) 2008-05-07
EE05088B1 (et) 2008-10-15
US6953854B2 (en) 2005-10-11
NO20024321D0 (no) 2002-09-10
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DE60100858D1 (de) 2003-10-30
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
HK1052348A1 (en) 2003-09-11
PE20011140A1 (es) 2001-11-01
WO2001070740A1 (en) 2001-09-27
ATE250601T1 (de) 2003-10-15
CN1188412C (zh) 2005-02-09
PL358253A1 (en) 2004-08-09
HUP0300591A3 (en) 2009-01-28
NO20024321L (no) 2002-09-10
EE200200545A (et) 2004-04-15
US6727363B2 (en) 2004-04-27
DE60100858T2 (de) 2004-07-29
AU780747B2 (en) 2005-04-14
EP1272489A1 (en) 2003-01-08
US20030149067A1 (en) 2003-08-07
EP1272489B1 (en) 2003-09-24
HUP0300591A2 (hu) 2003-07-28
JP2003528100A (ja) 2003-09-24
SI1272489T1 (en) 2004-02-29
IL150985A (en) 2007-03-08
KR20020081587A (ko) 2002-10-28

Similar Documents

Publication Publication Date Title
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
CN203777119U (zh) 跟腱延长术后康复支具
DE60044152D1 (de) Bupropion Metaboliten zur Behandlung von Angstzuständen
NZ526868A (en) Substituted alkylamine derivatives and methods of use for treating cancer and angiogenesis related disorders
GT200400098A (es) Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas.
IL186200A (en) Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
PL371428A1 (en) Substituted indolizine-like compounds and methods of use
MY167602A (en) Amine derivatives compounds for treating ophthalmic diseases and disorders
JO2505B1 (en) Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
MXPA05013469A (es) Derivados de piperazina y metodos de uso.
Sangkaew Distraction osteogenesis for the treatment of post traumatic complications using a conventional external fixator: a novel technique
CO5370677A1 (es) Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina
MXPA03006943A (es) Derivados de carbonilo sustituidos heterocicliclos y su uso como ligandos para el receptor d3 de la dopamina.
WO2002066469A3 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
WO2010011836A3 (en) Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
PA8519401A1 (es) Derivados de 3-azabiciclo(3.1.0)hexano utiles en terapia
PE20011140A1 (es) Proceso para preparar forma i cristalina de cabergolina
PE20011087A1 (es) Forma ii cristalina de cabergolina
NO20080393L (no) Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
AR033973A1 (es) Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprende
WO2014144584A3 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MXPA03006843A (es) Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure